A phase Ib/II study to investigate KTE-C19 and atezolizumab in patients with refractory, aggressive non-Hodgkin lymphoma (NHL)

Trial Profile

A phase Ib/II study to investigate KTE-C19 and atezolizumab in patients with refractory, aggressive non-Hodgkin lymphoma (NHL)

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Atezolizumab (Primary) ; Axicabtagene ciloleucel (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Kite Pharma
  • Most Recent Events

    • 21 Mar 2016 New trial record
    • 17 Mar 2016 This trial is expected to begin in 2016, according to a Kite Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top